We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims and Hers Expands Consumer-Focused Digital Health Platform
Read MoreHide Full Article
Key Takeaways
Hims & Hers added low testosterone care, menopause services and Labs to track biomarkers.
HIMS is expanding globally with Canada entry, U.K. weight-loss growth and a planned Eucalyptus deal.
TEM is advancing AI-driven diagnostics, while MED expands OPTAVIA access via HSA and FSA eligibility.
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , is building a consumer-first digital health platform aimed at expanding access to personalized, ongoing care through a technology-driven model. Its platform integrates telehealth consultations, electronic medical records, digital prescriptions and pharmacy fulfillment, allowing patients to access treatment for a range of conditions including sexual health, dermatology, hair loss, hormone health, mental health and weight management. The subscription-based model enables continuous engagement between patients and providers while supporting personalized treatment plans and follow-up care through its mobile and web interfaces.
HIMS has recently expanded its ecosystem with new specialties and proactive health offerings. These include a new category in men’s health focused on low testosterone treatments, as well as a menopause and perimenopause specialty on the Hers platform aimed at addressing underserved women’s health needs. In addition, the launch of Labs allows customers to track key biomarkers and receive doctor-developed action plans, while the introduction of a multi-cancer early detection test expands access to preventative screening and earlier diagnosis.
Alongside product expansion, Hims & Hers is scaling its global footprint. The company has entered Canada following the acquisition of a local digital health platform, expanded its weight-loss program in the U.K. and announced plans to acquire Eucalyptus, which is expected to extend its presence into additional international markets and strengthen its global consumer health platform.
TEM and MED Expanding Data-Driven Healthcare Platforms
Tempus AI, Inc. (TEM - Free Report) is advancing precision medicine by integrating artificial intelligence (AI) with large multimodal healthcare datasets to enable more personalized diagnostics and treatment decisions. Tempus AI leverages its platform of clinical, molecular and imaging data to develop intelligent diagnostics that help physicians match patients with more effective therapies. Recently, Tempus AI launched innovations such as the Paige Predict digital pathology solution and the HRD-RNA algorithm to improve biomarker identification, while also expanding collaborations with partners like Merck and leading health systems to accelerate AI-driven oncology research and screening initiatives.
Medifast, Inc. (MED - Free Report) is repositioning itself as a metabolic health company through its science-based, coach-guided wellness platform centered on the OPTAVIA system. Medifast combines structured nutrition plans, clinically informed products and behavioral coaching to help individuals improve metabolic health rather than focusing solely on short-term weight loss. Recently, Medifast strengthened this strategy by enabling eligible OPTAVIA programs to be reimbursed through HSA and FSA plans, expanding access to its metabolic health solutions while continuing to develop new systems and products aimed at supporting long-term metabolic balance and sustainable lifestyle change.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 33.6% over the past year, underperforming the industry’s decline of 23.6%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 1.8X is lower than the industry’s average of 3.5X and its five-year median of 2.7X. It carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2026 earnings per share suggests a flat performance compared with 2025.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Hims and Hers Expands Consumer-Focused Digital Health Platform
Key Takeaways
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , is building a consumer-first digital health platform aimed at expanding access to personalized, ongoing care through a technology-driven model. Its platform integrates telehealth consultations, electronic medical records, digital prescriptions and pharmacy fulfillment, allowing patients to access treatment for a range of conditions including sexual health, dermatology, hair loss, hormone health, mental health and weight management. The subscription-based model enables continuous engagement between patients and providers while supporting personalized treatment plans and follow-up care through its mobile and web interfaces.
HIMS has recently expanded its ecosystem with new specialties and proactive health offerings. These include a new category in men’s health focused on low testosterone treatments, as well as a menopause and perimenopause specialty on the Hers platform aimed at addressing underserved women’s health needs. In addition, the launch of Labs allows customers to track key biomarkers and receive doctor-developed action plans, while the introduction of a multi-cancer early detection test expands access to preventative screening and earlier diagnosis.
Alongside product expansion, Hims & Hers is scaling its global footprint. The company has entered Canada following the acquisition of a local digital health platform, expanded its weight-loss program in the U.K. and announced plans to acquire Eucalyptus, which is expected to extend its presence into additional international markets and strengthen its global consumer health platform.
TEM and MED Expanding Data-Driven Healthcare Platforms
Tempus AI, Inc. (TEM - Free Report) is advancing precision medicine by integrating artificial intelligence (AI) with large multimodal healthcare datasets to enable more personalized diagnostics and treatment decisions. Tempus AI leverages its platform of clinical, molecular and imaging data to develop intelligent diagnostics that help physicians match patients with more effective therapies. Recently, Tempus AI launched innovations such as the Paige Predict digital pathology solution and the HRD-RNA algorithm to improve biomarker identification, while also expanding collaborations with partners like Merck and leading health systems to accelerate AI-driven oncology research and screening initiatives.
Medifast, Inc. (MED - Free Report) is repositioning itself as a metabolic health company through its science-based, coach-guided wellness platform centered on the OPTAVIA system. Medifast combines structured nutrition plans, clinically informed products and behavioral coaching to help individuals improve metabolic health rather than focusing solely on short-term weight loss. Recently, Medifast strengthened this strategy by enabling eligible OPTAVIA programs to be reimbursed through HSA and FSA plans, expanding access to its metabolic health solutions while continuing to develop new systems and products aimed at supporting long-term metabolic balance and sustainable lifestyle change.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 33.6% over the past year, underperforming the industry’s decline of 23.6%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 1.8X is lower than the industry’s average of 3.5X and its five-year median of 2.7X. It carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2026 earnings per share suggests a flat performance compared with 2025.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.